Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin

Clinical Cancer Research

Volumn 13, Issue 16, 2007, Pages 4858-4866

  Unger, Clemens ^a   Häring, Brigitte ^a   Medinger, Michael ^a   Drevs, Joachim ^a   Steinbild, Simone ^a   Kratz, Felix ^a   Mross, Klaus ^a  

^a TUMOR BIOLOGY CENTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; ANTIEMETIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DIMETHYL SULFOXIDE; DOXORUBICIN; ETOPOSIDE; EXEMESTANE; FLUOROURACIL; LETROZOLE; LEUPRORELIN; METHOTREXATE; RAZOXANE; TAMOXIFEN; TROFOSFAMIDE;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANEMIA; ARTICLE; BALANITIS; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER REGRESSION; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONGESTIVE HEART FAILURE; CONSCIOUSNESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPHAGIA; DYSPNEA; EDEMA; ELECTROCARDIOGRAM; ERYTHEMA; EXTRAVASATION; FATIGUE; FEMALE; HEART BUNDLE BRANCH BLOCK; HEART VENTRICLE ARRHYTHMIA; HUMAN; LEUKOPENIA; LIPOSARCOMA; LUNG SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SIDE EFFECT; SKIN NECROSIS; SOMNOLENCE; STOMATITIS; T WAVE; THROMBOCYTOPENIA; VISUAL DISORDER; VOMITING;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; FEMALE; HEART; HUMANS; HYDRAZONES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PRODRUGS; SKIN;

EID: 34548106304     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2776     Document Type: Article

References (25)

1. Gianni L, Grasselli G, Cresta S, Locatelli A, Vigano L, Minotti G. Anthracyclines. Cancer Chemother Biol Response Modif 2003;21:29-40.
2. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185-229.
3. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339:900-5.
4. Elliott P. Pathogenesis of cardiotoxicity induced by anthracyclines. Semin Oncol 2006;33:S2-7.
5. Robert NJ, Vogel CL, Henderson IC, et al. The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. Semin Oncol 2004;31:106-46.
6. Kratz F, Warnecke A, Schmid B, Chung DE, Gitzel M. Prodrugs of anthracyclines in cancer chemotherapy. Curr Med Chem Anti-Canc Agents 2006;13:477-523.
7. Kratz F, Warnecke A, Scheuermann K, et al. Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives: improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound. J Med Chem 2002;45:5523-33.
8. Mansour AM, Drevs J, Esser N, et al. A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Cancer Res 2003;63:4062-6.
9. Warnecke A, Kratz F. Maleimide-oligo(ethylene glycol) derivatives of camptothecin as albumin-binding prodrugs: synthesis and antitumor efficacy. Bioconjugate Chem 2003;14:377-87.
10. Kratz F, Beyer U. Serum proteins as drug carriers of anticancer agents: a review. Drug Deliv 1998;5:281-99.
11. Kratz F, Ehling G, Kauffmann H, Unger C. Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)-hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin. Hum Exp Toxicol 2007;26:19-35.
12. Lebrecht D, Geist A, Ketelsen U, et al. The 6-maleimidocaproyl hydrazone derivative of doxorubicin (DOXO-EMCH) is superior to free doxorubicin with respect to cardiotoxicity and mitochondrial damage. Int J Cancer 2007;120:927-93.
13. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
14. Frost A, Gmehling D, Azemar M, Unger C, Mross K. Treatment of anthracycline extravasation with dexrazoxane - clinical experience. Onkologie 2006;29:314-8.
15. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97:2869-79.
16. Speth PA, van Hoesel QG, Haanen C. Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet 1988;15:15-31.
17. Eksborg S, Stendahl U, Lonroth U. Comparative pharmacokinetic study of adriamycin and 4′epiadriamycin after their simultaneous intravenous administration. Eur J Clin Pharmacol 1986;30:629-31.
18. Mross K, Maessen P, van der Vijgh WJ, Gall H, Boven E, Pinedo HM. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. J Clin Oncol 1988;6:517-26.
19. Eksborg S, Strandler HS, Edsmyr F, Naslund I, Tahvanainen P. Pharmacokinetic study of i.v. infusions of adriamycin. Eur J Clin Pharmacol 1985;28:205-12.
20. Mross K, Massing U, Kratz F. DNA-intercalators - the anthracyclines. In: Pinedo HM, Smorenburg VH, editors. Drugs affecting growth of tumors. Basel (Switzerland): Birkhäuser Verlag; 2006. p. 10-81.
21. Arcamone F, Animati F, Capranico G, et al. New developments in antitumor anthracyclines. Pharmacol Ther 1997;76:117-24.
22. Giannini G. Fluorinated anthracyclines: synthesis and biological activity. Curr Med Chem Anti-Canc Agents 2002;9:687-712.
23. Suarato A, Angelucci F, Geroni C. Ring-B modified anthracyclines. Curr Pharm Des 1999;5:217-27.
24. Haag R, Kratz F. Polymer therapeutics: concepts and applications. Angew Chem Int Ed Engl 2006;45:1198-215.
25. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000;65:271-84.